Cannabis Lab Testing Integrity: Standards, Challenges, and Regulatory Solutions

Executive Summary

Maryland has launched a comprehensive multi-laboratory audit program to combat "lab shopping," a practice where cannabis cultivators and processors submit samples to multiple testing facilities until they receive inflated THC results. The Maryland Cannabis Administration announced the initiative in September 2026, requiring all licensed testing laboratories to participate in blind proficiency testing and cross-laboratory verification protocols. The program represents one of the most aggressive state-level responses to widespread concerns about cannabis testing integrity, an issue that affects consumer safety, market fairness, and regulatory credibility across the United States.

Lab shopping exploits competitive pressures among testing facilities, creating incentives to report higher cannabinoid percentages than scientifically accurate. Inflated THC numbers command premium retail prices, but they mislead consumers and undermine product consistency. Maryland's audit framework mandates quarterly submission of identical homogenized samples to all licensed labs, with results published publicly and penalties ranging from fines to license suspension for facilities showing systematic bias. The program follows years of industry complaints and builds on enforcement models pioneered by Oregon and Michigan.

This enforcement shift arrives as federal rescheduling discussions intensify scrutiny on state regulatory frameworks. The Drug Enforcement Administration has cited testing inconsistencies as evidence of inadequate state oversight, making programs like Maryland's critical to demonstrating regulatory maturity. For multi-state operators, the initiative signals a trend toward standardized proficiency requirements that could reshape compliance budgets and laboratory vendor relationships nationwide.

Why Cannabis Lab Testing Integrity Matters

Testing integrity directly impacts patient safety, market competition, and the legitimacy of state regulatory programs overseeing a $30 billion annual U.S. cannabis market. Inaccurate cannabinoid and contaminant testing creates cascading problems across the supply chain.

For medical patients, inflated THC percentages make dosing unpredictable. A patient relying on consistent 20% THC flower who unknowingly purchases 15% THC product labeled as 25% experiences inadequate symptom relief. Conversely, a novice consumer purchasing what they believe is moderate-potency cannabis may experience adverse reactions if actual THC content exceeds labeled amounts. Pesticide and heavy metal testing failures pose direct health risks, particularly for immunocompromised patients using concentrated products.

Market dynamics amplify the problem. Retail shelves prioritize high-THC products, with percentage points translating directly to shelf placement and pricing power. Cultivators face pressure to achieve 25%+ THC results to remain competitive, creating demand for laboratories willing to provide favorable numbers. Honest testing facilities lose business to competitors offering "better" results, establishing a race-to-the-bottom dynamic. This market failure punishes quality-focused operators and rewards those gaming the system.

Regulatory credibility suffers when testing inconsistencies become public. Federal agencies evaluating state program adequacy under potential rescheduling frameworks cite testing failures as evidence of insufficient controls. State programs lose public trust when investigative reports reveal systematic inflation. The Food and Drug Administration has noted that inconsistent state testing undermines its ability to establish national product standards should cannabis move to Schedule III under the Controlled Substances Act.

Financial stakeholders face compliance and reputational risks. Multi-state operators must navigate varying testing standards across jurisdictions while maintaining brand consistency. Insurance underwriters struggle to assess product liability exposure when testing reliability remains uncertain. Capital markets discount valuations for companies operating in states with weak testing oversight, viewing regulatory risk as material to enterprise value.

Background and History of Cannabis Testing Integrity Issues

Cannabis lab testing integrity problems emerged alongside the first state medical programs but accelerated dramatically after 2014 when adult-use markets created high-stakes commercial incentives for inflated results.

Early Medical Program Era (1996-2013)

When California launched the nation's first medical cannabis program in 1996 under Proposition 215, no testing requirements existed. Patients and caregivers operated on trust and anecdotal experience. The first commercial cannabis testing laboratory, SC Labs, opened in California in 2010, offering voluntary cannabinoid profiling. Early testing focused on basic safety screening for mold and pesticides rather than potency verification.

Colorado and Washington established mandatory testing requirements when voters approved adult-use legalization in 2012. Colorado's Amendment 64 implementation rules required all cannabis products undergo testing for potency and contaminants before retail sale, effective January 2014. Washington's Initiative 502 included similar mandates. These requirements created the first regulated testing market, but initial oversight focused on laboratory accreditation rather than result accuracy.

The Inflation Crisis Emerges (2014-2018)

By 2016, investigative journalists and industry insiders began documenting systematic THC inflation. A 2016 analysis by cannabis testing expert Jeffrey Raber found that identical samples sent to different California laboratories returned THC results varying by more than 10 percentage points. Some facilities consistently reported results 15-20% higher than competitors testing the same material.

The economic incentive structure became clear: cultivators could submit samples to multiple labs until receiving desired results, then use the highest number for compliance and marketing. Laboratories competing for business faced pressure to deliver "competitive" results or lose clients. No state had implemented proficiency testing or cross-laboratory verification protocols to detect this practice.

Oregon documented the problem systematically in 2017 when the Oregon Liquor Control Commission conducted a pilot proficiency study. Regulators sent identical homogenized cannabis samples to all licensed laboratories. Results showed THC measurements ranging from 17% to 31% for the same material, a variance scientifically impossible given measurement uncertainty standards. The study revealed that some laboratories consistently reported results in the top quartile while others clustered around the mean, suggesting systematic bias rather than random error.

State Enforcement Begins (2018-2022)

Oregon responded to its 2017 findings by implementing mandatory proficiency testing in 2019. The Oregon Health Authority required all licensed laboratories to analyze blind reference samples quarterly, with results compared against known values and peer performance. Facilities showing consistent positive bias faced escalating penalties including license suspension. Three Oregon laboratories lost accreditation in 2020 after failing multiple proficiency rounds.

Michigan adopted similar requirements in 2020 following complaints from cultivators about inconsistent results. The Michigan Marijuana Regulatory Agency established a proficiency testing program using samples prepared by third-party reference material providers. Results became public record, allowing operators to evaluate laboratory performance before selecting testing partners.

California struggled with enforcement despite having the largest cannabis market. The state's Bureau of Cannabis Control (later absorbed into the Department of Cannabis Control) issued emergency regulations in 2019 requiring laboratories to participate in proficiency testing, but implementation stalled due to budget constraints and industry pushback. Not until 2022 did California complete its first mandatory proficiency round, revealing that 40% of licensed laboratories failed to meet acceptable performance criteria on at least one analyte.

Federal Scrutiny Intensifies (2022-2026)

The Department of Health and Human Services recommendation in August 2023 that DEA reschedule cannabis to Schedule III triggered new federal attention to state testing programs. The DEA's notice of proposed rulemaking, published in May 2024, included extensive discussion of state regulatory adequacy. Agency comments specifically cited testing inconsistencies as evidence that state programs lacked sufficient controls to ensure product safety and consistency.

Congressional oversight followed. A June 2025 Government Accountability Office report titled "Cannabis Testing: State Programs Show Inconsistent Oversight and Quality Control" documented that only 12 of 38 adult-use and medical states had implemented mandatory proficiency testing. The report found that laboratories in states without proficiency requirements showed THC inflation averaging 8-12% compared to states with active oversight programs.

Industry consolidation accelerated the problem in some markets. As multi-state operators acquired smaller cultivators and processors, they brought preferred laboratory vendors into new states, sometimes pressuring local facilities to match inflated results from other jurisdictions to maintain brand consistency. This created a race-to-the-top dynamic in THC percentages that further divorced labeled potency from actual content.

Maryland's Response (2026)

Maryland's Cannabis Administration announced its multi-laboratory audit program on September 26, 2026, following a year-long stakeholder process. The agency had documented complaints from cultivators about competitors using "friendly" labs and from consumers about inconsistent product experiences. A preliminary audit in early 2026 found THC variance of up to 18 percentage points for identical samples across Maryland's eight licensed testing facilities.

The Maryland program requires quarterly proficiency testing using homogenized flower and concentrate samples prepared by ISO-certified reference material providers. All licensed laboratories must analyze identical samples within a 72-hour window, with results submitted directly to regulators. The Cannabis Administration publishes aggregate results showing each laboratory's bias relative to consensus values, though individual facility names are anonymized in public reports for the first year to allow corrective action.

Key Players in the Testing Integrity Debate

State Regulatory Agencies

The Maryland Cannabis Administration leads the current enforcement initiative, building on its reputation for rigorous oversight established during the state's medical program launch in 2017. Director William Tilburg has stated that testing integrity represents a "foundational requirement" for market legitimacy and that the agency will not hesitate to suspend laboratories showing persistent bias.

The Oregon Health Authority pioneered proficiency testing requirements and maintains the most extensive public database of laboratory performance metrics. Oregon's program has served as a model for other states, though critics note that even with oversight, some inflation persists due to sampling methodology loopholes.

The Michigan Marijuana Regulatory Agency has taken aggressive enforcement action, suspending four laboratories between 2021 and 2025 for proficiency testing failures. Michigan's approach emphasizes transparency, publishing individual laboratory pass/fail rates and making historical performance data available to license applicants selecting testing partners.

The California Department of Cannabis Control oversees the nation's largest testing market with more than 30 licensed facilities. California has faced criticism for slow implementation of proficiency requirements and limited enforcement action despite documented problems. Budget constraints and political pressure from laboratory industry associations have hampered oversight efforts.

Testing Laboratories

SC Labs, the industry's oldest testing facility, has advocated for standardized proficiency testing and ISO 17025 accreditation requirements. The company operates in multiple states and has argued that rigorous oversight benefits compliant laboratories by eliminating unfair competition from facilities offering inflated results. SC Labs participates in voluntary inter-laboratory comparison programs and publishes its proficiency testing results publicly.

Steep Hill Laboratories, another multi-state testing provider, has pushed back against some proficiency testing designs, arguing that homogenized reference samples do not reflect real-world testing conditions and that natural product variability makes strict performance criteria inappropriate. The company advocates for measurement uncertainty reporting rather than pass/fail proficiency standards.

Regional laboratories in states without proficiency requirements have generally opposed mandatory oversight programs, citing implementation costs and arguing that market competition provides sufficient quality incentives. Industry associations representing smaller laboratories have lobbied against proficiency testing mandates in several states.

Industry Operators

Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have called for standardized testing requirements across jurisdictions. These companies face challenges maintaining brand consistency when the same genetics test at 22% THC in one state and 28% in another. MSOs have supported proficiency testing as a means to level the competitive playing field and reduce compliance complexity.

Craft cultivators have been divided. Some support rigorous testing oversight to prevent larger competitors from using inflated numbers to dominate retail shelf space. Others worry that strict proficiency standards will increase testing costs and reduce laboratory availability, particularly in rural areas with limited testing infrastructure.

Consumer and Patient Advocates

Americans for Safe Access, the nation's largest medical cannabis patient advocacy organization, has made testing integrity a priority issue. The group argues that inconsistent testing undermines physician confidence in recommending cannabis and puts patients at risk. ASA has called for federal minimum standards for state testing programs as part of any rescheduling framework.

The National Cannabis Industry Association has supported proficiency testing requirements while cautioning against overly prescriptive standards that could stifle laboratory innovation or create barriers to entry in testing markets. NCIA emphasizes that testing integrity serves industry interests by building consumer trust and regulatory credibility.

Legal and Regulatory Framework

Cannabis testing requirements exist entirely at the state level, as federal prohibition under 21 U.S.C. § 812 prevents FDA oversight of cannabis products sold in state-legal markets. This creates a patchwork of varying standards, enforcement mechanisms, and quality control requirements.

Most state cannabis laws delegate testing oversight to administrative agencies through enabling legislation. Maryland's medical cannabis law, enacted in 2013 and expanded for adult use in 2023, grants the Cannabis Administration broad authority to establish testing standards and laboratory licensing requirements. The agency's regulatory authority includes the power to mandate proficiency testing, set performance criteria, and suspend or revoke laboratory licenses for non-compliance.

State Administrative Procedure Acts govern how agencies implement and enforce testing requirements. Maryland's program operates under the Maryland Administrative Procedure Act, which requires public notice and comment periods for new regulations. The Cannabis Administration published its multi-laboratory audit program as an emergency regulation in September 2026, allowing immediate implementation while the formal rulemaking process continues.

Laboratory accreditation requirements vary by state. Most jurisdictions require ISO/IEC 17025 accreditation, an international standard for testing and calibration laboratories. However, ISO 17025 focuses on quality management systems and technical competence rather than result accuracy. Accreditation confirms that a laboratory follows proper procedures but does not verify that results are unbiased. This gap is what proficiency testing programs aim to address.

No federal statute currently governs cannabis testing, though this could change under rescheduling. If cannabis moves to Schedule III, the FDA would gain authority to regulate cannabis products as drugs or potentially as dietary supplements. FDA regulation would likely include Good Manufacturing Practice requirements and standardized testing protocols, preempting some state requirements. However, the agency has indicated that state-legal cannabis would remain in regulatory limbo until Congress acts to resolve the conflict between federal scheduling and state legalization.

Professional liability and insurance law creates additional pressure for testing accuracy. Laboratories face potential negligence claims if inaccurate results lead to consumer harm. Several product liability lawsuits have named testing laboratories as defendants, arguing that inflated THC results or missed contaminants constitute professional malpractice. Insurance carriers have responded by requiring laboratories to maintain proficiency testing records and quality control documentation as conditions of coverage.

State-by-State Testing Oversight Landscape

Testing requirements and oversight rigor vary dramatically across the 38 states with medical or adult-use cannabis programs. The following breakdown covers states with the most developed oversight frameworks and those where Maryland's approach may influence future policy.

Oregon

Oregon requires mandatory quarterly proficiency testing for all licensed laboratories. The Oregon Health Authority contracts with third-party providers to prepare homogenized reference samples covering cannabinoids, pesticides, heavy metals, and microbial contaminants. Laboratories must achieve z-scores within acceptable ranges (typically ±2 standard deviations from consensus values) to maintain licensure. Results are published quarterly with individual laboratory performance data available to the public. Oregon has suspended or revoked licenses for five laboratories since implementing the program in 2019. The state also requires laboratories to report measurement uncertainty with all results.

Michigan

Michigan's Marijuana Regulatory Agency mandates proficiency testing twice annually using samples from ISO-certified reference material providers. Laboratories must meet performance criteria for cannabinoid potency, pesticides, heavy metals, mycotoxins, and residual solvents. The state publishes pass/fail rates for each laboratory and requires facilities that fail any analyte to submit corrective action plans and undergo additional testing before resuming operations. Michigan suspended four laboratories in 2024 for repeated proficiency failures. The state also prohibits laboratories from accepting samples from the same batch at multiple facilities, directly targeting lab shopping.

California

California requires ISO 17025 accreditation and participation in proficiency testing programs, but enforcement has been inconsistent. The Department of Cannabis Control contracts with third-party providers for proficiency samples but has not published comprehensive performance data or taken significant enforcement action against failing laboratories. The state's large testing market (over 30 licensed facilities) and political pressure from industry associations have complicated oversight efforts. California does require laboratories to report measurement uncertainty and maintain detailed quality control records subject to inspection.

Colorado

Colorado's Marijuana Enforcement Division requires laboratories to participate in proficiency testing but does not mandate specific programs or publish results. Laboratories must maintain ISO 17025 accreditation and submit to annual inspections. The state has taken limited enforcement action for testing failures, instead relying on market competition and accreditation requirements to ensure quality. Colorado does prohibit the same sample from being tested at multiple laboratories without regulatory approval, though enforcement of this provision has been limited.

Massachusetts

Massachusetts requires quarterly proficiency testing for all licensed laboratories, with results submitted to the Cannabis Control Commission. The state publishes aggregate performance data but does not identify individual laboratories publicly. Massachusetts has suspended two laboratories for proficiency failures since implementing the requirement in 2020. The state also requires laboratories to analyze samples within strict time frames to prevent degradation and mandates chain-of-custody documentation for all samples.

Illinois

Illinois requires ISO 17025 accreditation and proficiency testing participation but has not implemented a mandatory state-administered program. Laboratories must participate in third-party proficiency programs and maintain records available for inspection. The state has focused enforcement efforts on contaminant testing failures rather than potency inflation, though the Department of Financial and Professional Regulation has authority to address systematic bias.

New York

New York's Office of Cannabis Management requires laboratories to participate in proficiency testing programs approved by the state. The agency has not yet implemented a mandatory state-administered program but has indicated that one is under development. New York requires ISO 17025 accreditation and maintains strict chain-of-custody requirements. The state's adult-use market launched in 2022, and testing oversight is still evolving.

Florida

Florida's medical cannabis program requires laboratory licensure but does not mandate proficiency testing. The state requires ISO 17025 accreditation and conducts inspections, but has not implemented systematic oversight of result accuracy. Florida's vertically integrated license structure, where operators control their own testing, has raised particular concerns about conflicts of interest and result manipulation.

Market and Business Implications

Testing integrity initiatives reshape competitive dynamics, compliance costs, and capital allocation across the cannabis supply chain.

For cultivators and processors, rigorous testing oversight eliminates the competitive advantage of lab shopping but may reveal that actual product potency falls below marketed levels. Operators who have built brands around high-THC claims face difficult decisions about reformulating products, adjusting marketing, or accepting lower price points. Some cultivators have responded by investing in genetics and cultivation techniques that genuinely produce higher cannabinoid levels rather than relying on favorable testing.

Testing laboratories face a market correction. Facilities that competed on inflated results lose business as proficiency testing exposes bias. Compliant laboratories gain market share but face pressure to reduce pricing as the competitive landscape shifts. Laboratory consolidation has accelerated, with multi-state testing companies acquiring regional facilities and implementing standardized quality control protocols. Testing costs have increased in states with rigorous oversight, adding $200-500 per batch to compliance expenses.

Retailers must navigate consumer expectations shaped by years of inflated THC numbers. Products genuinely testing at 18-22% THC may struggle to compete with legacy inventory labeled at 28-32%, even if actual potency was similar. Some retailers have responded by emphasizing terpene profiles, minor cannabinoids, and overall product quality rather than focusing exclusively on THC percentage. Budtender training has shifted to educate consumers about the limitations of THC as a quality metric.

Multi-state operators face complex compliance challenges. Maintaining brand consistency across jurisdictions with varying testing standards requires sophisticated quality control and supply chain management. Some MSOs have responded by establishing internal testing protocols more rigorous than state requirements, using third-party verification to ensure products meet brand specifications regardless of jurisdiction. This approach increases costs but reduces regulatory and reputational risk.

Investment implications are significant. Cannabis companies operating in states with weak testing oversight face regulatory risk as enforcement trends toward Maryland's model. Due diligence for mergers and acquisitions increasingly includes testing compliance audits, with buyers discounting valuations for targets with history of suspicious results. Public companies face securities law exposure if marketed THC levels materially misrepresent actual product potency, potentially triggering shareholder litigation.

The broader market impact includes downward pressure on wholesale prices for high-THC flower as testing integrity improves. Oregon data shows that average tested THC percentages declined from 24% to 21% in the two years following proficiency testing implementation, with corresponding wholesale price compression. This suggests that some of the premium pricing for high-THC products reflected inflated testing rather than superior genetics or cultivation.

What Testing Experts and Industry Leaders Say

According to Dr. Jeffrey Raber, founder of The Werc Shop and a pioneer in cannabis testing science, proficiency testing represents the minimum standard for credible laboratory oversight. Raber has stated that measurement uncertainty in cannabis testing makes results within 10-15% of each other potentially acceptable, but the 20-30% variances documented in some states indicate systematic problems rather than natural variation.

Josh Wurzer, president of SC Labs, has argued that transparency and accountability benefit the entire industry. According to Wurzer, laboratories that provide accurate results should welcome proficiency testing as a competitive differentiator. He has noted that SC Labs publishes its proficiency testing results and measurement uncertainty data to demonstrate commitment to accuracy.

Regulatory officials emphasize that testing integrity underpins market legitimacy. William Tilburg, director of the Maryland Cannabis Administration, has stated that the agency views testing oversight as non-negotiable and that laboratories unwilling to participate in rigorous proficiency programs should not hold licenses. According to Tilburg, consumer trust and regulatory credibility depend on confidence that labeled potency reflects actual content.

Patient advocates stress health and safety implications. Debbie Churgai, director of Americans for Safe Access, has stated that medical cannabis patients need accurate potency information to dose effectively and that testing failures put vulnerable populations at risk. According to Churgai, federal rescheduling should include minimum testing standards to ensure patient safety across all state programs.

Industry economists note that testing inflation creates market inefficiencies. Beau Whitney, senior economist at Whitney Economics, has stated that inflated THC numbers distort price discovery and resource allocation, leading to overinvestment in high-THC genetics at the expense of product diversity. According to Whitney, correcting testing bias would improve market efficiency and encourage innovation in minor cannabinoids and terpene profiles.

Some laboratory operators have expressed concerns about proficiency testing design. Representatives from Steep Hill Laboratories have argued that homogenized reference samples do not reflect real-world testing conditions and that strict pass/fail criteria may not account for legitimate methodological differences between laboratories. However, most testing experts counter that proficiency testing using standardized samples represents the only practical way to verify result accuracy at scale.

What's Next for Cannabis Testing Oversight

Maryland's program will likely influence testing policy in multiple states over the next 12-24 months as regulators evaluate its effectiveness and industry adapts to heightened oversight.

The Maryland Cannabis Administration will publish its first quarterly proficiency testing results in January 2027, providing the first comprehensive data on laboratory performance under the new program. Regulators have indicated that laboratories showing persistent positive bias will face escalating enforcement, beginning with corrective action requirements and potentially progressing to license suspension for repeated failures.

Several states are developing similar programs. New Jersey's Cannabis Regulatory Commission announced in August 2026 that it is designing a mandatory proficiency testing program modeled on Maryland's approach, with implementation targeted for mid-2027. Connecticut and Rhode Island have both issued requests for information seeking vendors to provide proficiency testing services, suggesting programs may launch in 2027.

Federal rescheduling proceedings will influence state testing requirements. The DEA's final rule on Schedule III placement, expected in late 2026 or early 2027, may include commentary on state program adequacy that references testing oversight. If the agency conditions state program recognition on proficiency testing requirements, states without such programs may face pressure to implement them quickly.

Industry consolidation in the testing sector will likely accelerate. Laboratories unable or unwilling to meet proficiency testing requirements will exit the market or be acquired by larger operators with established quality control infrastructure. This consolidation may reduce testing capacity in some markets, potentially increasing costs and turnaround times.

Technology developments may improve testing accuracy and reduce opportunities for manipulation. Emerging technologies including portable spectrometers and blockchain-based chain-of-custody systems could make sample switching and result manipulation more difficult. However, these technologies remain in early stages and have not yet achieved the accuracy and reliability of traditional laboratory methods.

Consumer education efforts will need to address the gap between historical THC claims and actual potency. Retailers and regulators face the challenge of explaining why products that previously tested at 30% THC now test at 22% without undermining confidence in the testing system. Some states are considering requiring labels to include measurement uncertainty ranges rather than single-point potency values.

Legal challenges to proficiency testing requirements remain possible. Laboratory industry associations have threatened litigation in some states, arguing that mandatory proficiency testing exceeds regulatory authority or imposes unreasonable burdens. However, legal experts generally agree that states have broad authority to establish licensing requirements for laboratories handling controlled substances.

Further Reading and Primary Sources

• Maryland Cannabis Administration Multi-Laboratory Audit Program regulations: https://mca.maryland.gov/regulations/testing-oversight
• Oregon Health Authority Cannabis Testing Laboratory Proficiency Testing Program: https://www.oregon.gov/oha/ph/diseasesconditions/communicabledisease/marijuana/pages/testing.aspx
• Michigan Marijuana Regulatory Agency Laboratory Licensing and Proficiency Testing: https://www.michigan.gov/mra/testing
• Government Accountability Office, "Cannabis Testing: State Programs Show Inconsistent Oversight and Quality Control" (June 2025): https://www.gao.gov/products/gao-25-104
• ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories: https://www.iso.org/standard/66912.html
• California Department of Cannabis Control Testing Regulations: https://cannabis.ca.gov/cannabis-laws/dcc-regulations/
• Americans for Safe Access Medical Cannabis Testing Standards: https://www.safeaccessnow.org/testing_standards
• National Institute of Standards and Technology Cannabis Quality Assurance Program: https://www.nist.gov/programs-projects/cannabis-quality-assurance-program
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024): https://www.federalregister.gov/documents/2024/05/21/cannabis-scheduling
• 21 U.S.C. § 812 - Schedules of controlled substances: https://www.law.cornell.edu/uscode/text/21/812